Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Eckerd Sale Complete

This article was originally published in The Pink Sheet Daily

Executive Summary

CVS and Jean Coutu have completed the acquisition of the Eckerd pharmacy franchise from J.C. Penney, the retailers announced Aug. 1

CVS and Jean Coutu have completed the acquisition of the Eckerd pharmacy franchise from J.C. Penney, the retailers announced Aug. 1.

Coutu acquired 1,549 Eckerd stores for $2.4 bil. The acquisition makes the Canadian company the fourth largest retail pharmacy chain in North America (1 (Also see "Eckerd Will Be Centerpiece Of Cross-Border Pharmacy Chain Under Coutu" - Pink Sheet, 9 Apr, 2004.)).

CVS acquired the remaining 1,260 Eckerd stores and the chains $1 bil. per year mail order operations, making CVS the largest chain in the U.S. CVS paid $2.2 bil. for the assets (2 (Also see "CVS Doubles PBM Business Through $2.2 Bil. Eckerd Deal" - Pink Sheet, 5 Apr, 2004.)).

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS060341

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel